Text Size

Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events

This study is currently recruiting participants.
Verified October 2012 by Cornell University
Sponsor:
Information provided by (Responsible Party):
Cornell University
ClinicalTrials.gov Identifier:
NCT01699841
First received: October 2, 2012
Last updated: NA
Last verified: October 2012
History: No changes posted
  Purpose

The purpose of this study is to understand how breast milk may protect infants from infection and promote favorable immunological, growth and development outcomes. By following mothers and their infants, we will evaluate the important interactions between infant immune responses and infectious disease events in relation to breast milk composition and feeding patterns. Our aim is to identify a set of predictive factors corresponding to healthy early infant growth and development in this setting in Northern Tanzania.


Condition
HIV
Malnutrition
Cryptosporidiosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Cornell University:

Primary Outcome Measures:
  • Breast milk composition [ Time Frame: Up to 6 months post-partum ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Infant anthropometric measures [ Time Frame: Up to 6 months of age ] [ Designated as safety issue: No ]
  • Infant infectious disease events [ Time Frame: Up to 6 months of age ] [ Designated as safety issue: No ]

Estimated Enrollment: 208
Study Start Date: April 2012
Groups/Cohorts
HIV+ and HIV- mothers and their infants

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

HIV+ and HIV- mothers and their infants attending a semi-rural clinic and/or rural dispensaries from birth to 6 months of infant age in north western Tanzania.

Criteria

Inclusion Criteria:

  • Informed consent provided by mothers, and parental consent on behalf of their infants
  • Confirmed maternal HIV status (HIV-1, HIV-2 or HIV-Dual seropositive or HIV-seronegative)
  • Stated intention to remain in the clinic catchment area ≥6 months post-partum
  • Singleton birth

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01699841

Contacts
Contact: Joann M. McDermid, PhD 607-255-2490 jmm585@cornell.edu

Locations
Tanzania
Kisesa Health Centre Recruiting
Kisesa, Tanzania
Contact: Joann M. McDermid, PhD     607-255-2490     jmm585@cornell.edu    
Principal Investigator: Joann M. McDermid, PhD            
Sponsors and Collaborators
Cornell University
  More Information

No publications provided

Responsible Party: Cornell University
ClinicalTrials.gov Identifier: NCT01699841     History of Changes
Other Study ID Numbers: IRB 1111002616
Study First Received: October 2, 2012
Last Updated: October 2, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Communicable Diseases
Cryptosporidiosis
Malnutrition
Infection
Intestinal Diseases, Parasitic
Parasitic Diseases
Protozoan Infections, Animal
 Parasitic Diseases, Animal
Coccidiosis
Protozoan Infections
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Nutrition Disorders

ClinicalTrials.gov processed this record on March 07, 2013